XML 53 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
16. Subsequent Event
12 Months Ended
Dec. 31, 2012
Subsequent Event [Line Items]  
Subsequent Events [Text Block]
16. SUBSEQUENT EVENT

In January 2013, we acquired 100% of the outstanding shares of AbD Serotec, a division of MorphoSys AG, for approximately 53 million Euros (approximately $70 million) in cash. The acquisition will be included in our Life Science segment's results of operations from the acquisition date and will be accounted for as a business combination. The amount of acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill to be recorded will not be deductible for income tax purposes. We are unable to complete the fair value of the net assets acquired, as more time is needed to complete the information transfer from the seller and include all information into a valuation of individual assets and liabilities. We believe that with AbD Serotec's comprehensive catalog of antibodies, we will be able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA and cell sorting.